Vertex Pharmaceuticals Inc. diskutieren
Vertex Pharmaceuticals Inc.
WKN: 882807 / Symbol: VRTX / Name: Vertex / Aktie / Biotechnologie & medizinische Forschung / Large Cap /
453,20 €
0,85 %
Buy Vertex Pharmaceuticals Inc.
Buy Vertex Pharmaceuticals Inc.
Buy Vertex Pharmaceuticals Inc.
Buy Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is now covered by analysts at William Blair. They set an "outperform" rating and a $382.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $410.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at BMO Capital Markets from $385.00 to $389.00. They now have an "outperform" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $380.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $370.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $456.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $370.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at HC Wainwright from $380.00 to $390.00. They now have a "buy" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Cantor Fitzgerald from $370.00 to $380.00. They now have an "overweight" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at BMO Capital Markets from $389.00 to $415.00. They now have an "outperform" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $380.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $380.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Barclays PLC from $408.00 to $415.00. They now have an "overweight" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Neueste Beiträge
The_Goldman_Sachs_Gr in Cemex SAB de CV ADR diskutieren